ɣ-H2AX immunohistochemistry, performed as a biomarker of DNA DSBs, showed low levels background staining in talazoparib treated tumours and high levels of positive staining in both the LuTate and combination treated tumours. The gene discussed is H2AX; the disease is neoplasm.